Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is NeuroOne Medical Technologies EV-to-EBITDA?
NeuroOne Medical TechnologiesNMTC +18.83%21 EV-to-EBITDA is -2.00 as of Aug. 13, 2026. GuruFocus rates NMTC with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 514 Medical Devices & Instruments companies, NeuroOne Medical Technologies ranks worse than 194552.33% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NeuroOne Medical Technologies's enterprise value is $13.33 Mil.
NeuroOne Medical Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.67 Mil. Therefore, NeuroOne Medical Technologies's EV-to-EBITDA for today is -2.00.
The historical rank and industry rank for NeuroOne Medical Technologies's EV-to-EBITDA or its related term are showing as below:
NMTC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.71 Med: -2.3 Max: 0.35
Current: -2
During the past 13 years, the highest EV-to-EBITDA of NeuroOne Medical Technologies was 0.35. The lowest was -13.71. And the median was -2.30.
NMTC's EV-to-EBITDA is ranked worse than 100% of 514
companies
in the Medical Devices & Instruments industry
Industry Median: 14.825
vs NMTC: -2.00
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
NeuroOne Medical Technologies (NAS:NMTC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NeuroOne Medical Technologies's PE Ratio (TTM) for today is calculated as:
NeuroOne Medical Technologies's share price for today is $1.845.
NeuroOne Medical Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.880.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NeuroOne Medical Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroOne Medical Technologies EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NeuroOne Medical Technologies's EV-to-EBITDA falls into.
NeuroOne Medical Technologies's current Enterprise Value is $13.33 Mil.
NeuroOne Medical Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroOne Medical Technologies (NMTC) has a EV-to-EBITDA of -2.00 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NeuroOne Medical Technologies. According to the industry distribution chart, NeuroOne Medical Technologies ranks #999999 out of 514 companies in the Medical Devices & Instruments industry.
Is NeuroOne Medical Technologies' EV-to-EBITDA too high?
NeuroOne Medical Technologies' current EV-to-EBITDA is -2.00. Based on the distribution chart, NeuroOne Medical Technologies ranks #999999 out of 514 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NeuroOne Medical Technologies has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' EV-to-EBITDA compare to CSDX and IRIX?
According to the Medical Devices & Instruments industry distribution chart, NeuroOne Medical Technologies ranks #999999 out of 514 companies for EV-to-EBITDA. This places NeuroOne Medical Technologies in the lower half of its industry. The industry median EV-to-EBITDA is 14.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.83, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NeuroOne Medical Technologies. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroOne Medical Technologies's current EV-to-EBITDA is -2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
NeuroOne Medical Technologies (NMTC) has a current EV-to-EBITDA of -2.00. The current EV-to-EBITDA is -2.00. NeuroOne Medical Technologies' overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current EV-to-EBITDA is -2.00 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
21GF Score
Get the complete analysis for NMTC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NMTC has been successfully added to your 
